COVID-19 and the Immunology Market Recorded Webinar | Antoine Grey | From: Jan 28, 2021 - To: Dec 31, 2021 |
Impact of the COVID-19 Pandemic on the Sales of Immunology Drugs
The COVID-19 pandemic has been caused by the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world, leading to intense disruption across the healthcare industry in all affected countries. This disruption, coupled with the uncertainty of how immunosuppressive medication will interact with the disease, has led to severe difficulties for patients with immunological disorders seeking treatment, especially as many of these conditions require ongoing immunosuppressive therapy.
Due to the nature of these drugs, many immunosuppressives in the immunology sector, particularly biologic treatments that treat autoimmune disease, have been affected by the pandemic. Initially, fear that these drugs would contribute to the risk of contracting COVID-19 led to a drop in sales for some of these drugs. However, evidence from the past 9 months has since come to light on the risks and benefits of these drugs and medical organizations have released their recommendations and guidance on the impacts of COVID-19 on their patients. Further, many of these drugs have been studied for the treatment of COVID-19 directly, leading to a change in perception of the safety of biological therapies in autoimmune disease.
In this webinar Antoine Grey, a Senior Healthcare Analyst will present the changing immunology market landscape, drawing insights from GlobalData’s report, ‘Impact of the COVID-19 Pandemic on the Sales of Immunology Drugs’. The dynamic performance of key players in the immunology sector will be covered, including a discussion on GlobalData’s short-term sales forecast for these drugs. The webinar will include insights from high-prescribing physicians across the dermatology, gastroenterology, and rheumatology fields covering the challenges of treating their patients posed by the pandemic, as well as their expectations over the next couple of years.
Key Learning Objectives:-
Who Will Benefit?
Antoine Grey,
Senior Healthcare Analyst
Antoine Grey, MBiochem, is an Analyst in the Immunology team at GlobalData’s London office. Having started in August 2017, his responsibilities involve writing reports and providing strategic analysis on immunological diseases and their treatments, as well as writing Expert Insights on relevant healthcare news. Prior to GlobalData, Antoine graduated from the University of Oxford with an MBiochem in Biochemistry (Molecular & Cellular), which involved looking at how AdipoRon, a potent adiponectin receptor agonist, affected insulin resistance and skeletal muscle cell development in mice and undertook a summer internship in the Virology marketing department of Bristol-Myers Squibb.
Heather Leach,
Therapy Area Director
Heather Leach, Ph.D., is the Director of Immunology at GlobalData in Boston. Heather has 10 years of basic research experience in molecular biology and immunology and over five years of experience as an analyst and consultant for the biopharmaceutical industry. Previously, Heather served as GlobalData’s Director of Oncology and Hematology. Prior to joining GlobalData’s oncology group, she worked as an analyst in both immunology and neurology, and as a consultant for a boutique life sciences consulting firm in New York City. She has worked in various academic and pharmaceutical research labs at the University of Connecticut, Boston University School of Medicine, and Pfizer, covering human diseases such as sepsis, systemic sclerosis, and idiopathic pulmonary fibrosis. Heather holds a Bachelor’s degree in Molecular and Cell Biology from the University of Connecticut, and a Ph.D. in Pathology and Cell and Molecular Biology from Boston University School of Medicine.
